menu
    • menu
    [{"orgOrder":0,"company":"Aker BioMarine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NORWAY","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Bifidobacterium Lactis","moa":"||Gut microbiome","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Aker BioMarine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Aker BioMarine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aker BioMarine \/ Undisclosed"},{"orgOrder":0,"company":"PanTheryx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Bifidobacterium","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"PanTheryx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"PanTheryx \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PanTheryx \/ Undisclosed"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Lactobacillus Rhamnosus","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"Fonterra Research Centre","sponsor":"Xinhua Hospital, Shanghai Jiaotong University School of Medicine | Sprim Advanced Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NEW ZEALAND","productType":"Probiotic","year":"2012","type":"Inapplicable","leadProduct":"Lactobacillus Rhamnosus","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fonterra Research Centre","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fonterra Research Centre \/ Xinhua Hospital, Shanghai Jiaotong University School of Medicine | Sprim Advanced Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Fonterra Research Centre \/ Xinhua Hospital, Shanghai Jiaotong University School of Medicine | Sprim Advanced Life Sciences"}]

    Find Clinical Drug Pipeline Developments & Deals for Lactobacillus Rhamnosus

    Menu

    Lactobacillus Rhamnosus

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aker BioMarine

                            Norway arrow
                            Neuroscience
                            Not Confirmed

                            Aker BioMarine

                            Norway arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bifidobacterium Lactis,Lactobacillus Gasseri,Lactobacillus Rhamnosus

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioma Probiotics Launches Women’s Gut Health Formula for Natural Weight Loss

                            Details : Bioma Probiotics supports weight loss, balances gut health, and helps women reduce bloating, boost energy, and improve digestion naturally.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            August 05, 2025

                            Lead Product(s) : Bifidobacterium Lactis,Lactobacillus Gasseri,Lactobacillus Rhamnosus

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PanTheryx

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            PanTheryx

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bifidobacterium,Lactobacillus Rhamnosus

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TruBiotics® Grows Its Family: New Baby Drops Feature Clinically Researched Probiotic Strain BB-12® Shown to ...

                            Details : Kids Chewable probiotic supplements, TruBiotics (Bifidobacterium) and Lactobacillus launched by company, the two most-clinically researched probiotic types to support digestive and immune heath for children.

                            Product Name : TruBiotics

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            March 02, 2022

                            Lead Product(s) : Bifidobacterium,Lactobacillus Rhamnosus

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Northwell Health

                            Country arrow
                            Neuroscience
                            Not Confirmed

                            Northwell Health

                            Country arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Rhamnosus

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan

                            Details : Lactobacillus Rhamnosus is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            December 17, 2020

                            Lead Product(s) : Lactobacillus Rhamnosus

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Fonterra Research Centre

                            Country arrow
                            Neuroscience
                            Not Confirmed

                            Fonterra Research Centre

                            Country arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lactobacillus Rhamnosus

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Xinhua Hospital, Shanghai Jiaotong University School of Medicine | Sprim Advanced Life Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of 12-week Probiotic Supplementation on Bacterial and Viral Infections in Infants Aged 6 to 12 Months.

                            Details : Lactobacillus Rhamnosus is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Infections.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            November 09, 2012

                            Lead Product(s) : Lactobacillus Rhamnosus

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Xinhua Hospital, Shanghai Jiaotong University School of Medicine | Sprim Advanced Life Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth